阿立哌唑治疗双相抑郁：国内文献的循证医学评价

Aripiprazole for Treatment of Bipo-lar Depression: Evidence-Based Medicine Study from Domestic Data

摘要: 目的：评价分析阿立哌唑治疗双相抑郁的作用。方法：通过数据检索，对5项阿立哌唑联合碳酸锂与碳酸锂治疗双相抑郁的研究资料进行meta分析，评价有效率的差异和症状改善的差异。结果：1、有效率：通过异质性检验，X2 = 0.68，df = 3，P =0.88，I2 = 0%，OR为1.01，95%可信区间为(0.62, 1.63)，Z = 0.02，P = 0.98，提示阿立哌唑联合碳酸锂与碳酸锂相比较无统计学差异。2、症状学评价：异质性检验，X2 = 170.73，df = 9，P < 0.01，I2 = 94.7%，WMD为−5.43，95%可信区间为(−5.40, −5.27)；合并效应检验：Z = 64.64，P < 0.01。提示阿立哌唑联合碳酸锂与碳酸锂相比，症状评分更低。结论：阿立哌唑联合碳酸锂可以使症状改善提前，症状改善更明显。

Abstract: Objective: To analyze the effects aripiprazole for treatment of bipolar. Method: The difference on effective rate and symptom change was assessed between two groups (combination of aripiprazole and lithium v lithium) in 5 studies from searching Chinese medical database. Results: No difference on effective rate is found between combination group and lithium carbonate group (OR =1.01, 95% CI = 0.62~1.63, Z = 0.02, P = 0.98). The scale of depressive symptoms is lower in combination group than that in lithium carbonate group (WMD = −5.43, 95% CI = −5.40~−5.27, Z = 64.64, P < 0.01). Conclusion: Combination group of aipiprazole and lithium has a more early therapeutic effect and more significant change in symptoms than lithium carbonate group.